SCHEMBL12038296

SCHEMBL12038296

CC(=O)OCOc1c(Cl)cc2cc(C(=O)ON3C(=O)CCC3=O)c(=O)oc2c1F

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOB P27338 6/20 0.37
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ MAOA P21397 2/20 0.33
▸ ALDH1A1 P00352 4/20 0.32
▸ HPGD P15428 3/20 0.32
▸ HSD17B10 Q99714 2/20 0.32
▸ USP2 O75604 1/20 0.32
▸ POLB P06746 1/20 0.32
▸ ALOX15 P16050 1/20 0.32
▸ ALOX12 P18054 1/20 0.32
▸ CASP1 P29466 1/20 0.32
▸ CASP7 P55210 1/20 0.32
▸ GPR35 Q9HC97 1/20 0.32
▸ MAPT P10636 3/20 0.31
▸ KDM4E B2RXH2 3/20 0.30
▸ GLA P06280 2/20 0.30
▸ GAA P10253 2/20 0.30
▸ TP53 P04637 1/20 0.30
▸ MAPK1 P28482 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12038332 0.90 MAOB (0.34) MAOBMEN1KMT2AMAOAALDH1A1
SCHEMBL12038297 0.90 MAOB (0.39) MAOBMEN1KMT2AMAOAALDH1A1
SCHEMBL12038299 0.86 MEN1 (0.39) MAOBMEN1KMT2AMAOAALDH1A1
SCHEMBL12038354 0.85 MAPT (0.33) MAOBMAOAMAPT
SCHEMBL12038292 0.83 MAOB (0.37) MAOBMEN1KMT2AMAOAALDH1A1
SCHEMBL12038291 0.82 MEN1 (0.37) MAOBMEN1KMT2AMAOAALDH1A1
SCHEMBL12038362 0.81 MAOB (0.34) MAOBMEN1KMT2AMAOAMAPT
SCHEMBL12038366 0.81 MAOB (0.32) MAOBMAOAALDH1A1HPGDHSD17B10
SCHEMBL12038303 0.81 MAOB (0.40) MAOBMEN1KMT2AMAOAALDH1A1
SCHEMBL12038326 0.80 MEN1 (0.33) MAOBMEN1KMT2AMAOAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8318953-B2 Reactive coumarin derivatives and their use in cellular analyses AAT BIOQUEST, INC. (US) 2012-11-27 — — US disclosed
US-8318953-B2 Reactive coumarin derivatives and their use in cellular analyses AAT BIOQUEST, INC. (US) 2012-11-27 — — US disclosed
US-20110318772-A1 REACTIVE COUMARIN DERIVATIVES AND THEIR USE IN CELLULAR ANALYSES AAT BIOQUEST, INC. (US) 2011-12-29 — — US disclosed
US-20110318772-A1 REACTIVE COUMARIN DERIVATIVES AND THEIR USE IN CELLULAR ANALYSES AAT BIOQUEST, INC. (US) 2011-12-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110318772-A1 REACTIVE COUMARIN DERIVATIVES AND THEIR USE IN CELLULAR ANALYSES CYP3A7, XPO7, HCCS MAOB 3197/4885MEN1 3357/4885KMT2A 4772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback